A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Clinical trial NCT06875310 · RECRUITING

Trial details

NCT number: NCT06875310
Sponsor: Mirati Therapeutics Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2025-04-24
Primary completion: 2029-09-07
Enrollment: 630

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.